Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arvinas Holding Company LLC

7.56
+0.16002.16%
Volume:226.97K
Turnover:1.69M
Market Cap:519.92M
PE:-2.73
High:7.61
Open:7.33
Low:7.23
Close:7.40
Loading ...

Company Profile

Company Name:
Arvinas Holding Company LLC
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
430
Office Location:
5 Science Park,395 Winchester Avenue,New Haven,Connecticut,United States
Zip Code:
06511
Fax:
- -
Introduction:
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Directors

Name
Position
John Houston
Chief Executive Officer, President and Director
Timothy Shannon
Chairman of the Board of Director
Andrew Levin
Director
Bradley Margus
Director
Briggs W. Morrison
Director
E. Jonathan Soderstrom
Director
Edward Kennedy, Jr.
Director
Jakob Loven
Director
Kush M. Parmar
Director
Liam Ratcliffe
Director
Stephen Squinto
Director

Shareholders

Name
Position
John Houston
Chief Executive Officer, President and Director
Andrew Crew
Senior Vice President, Chemistry
Ian Taylor
Senior Vice President, Biology
Sean Cassidy
Chief Financial Officer